Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Sophiris Bio Presents Topsalysin Data from Phase 2a Proof
Transcript
May 15, 2017 Sophiris Bio Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Cancer at 112th American Urological Association (AUA) Meeting SAN DIEGO and VANCOUVER, British Columbia, May 15, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) as a first-inclass treatment for urological diseases, today announced that successful data from its Phase 2a proof-of-concept study of topsalysin, which evaluated the drug as a focal treatment for localized prostate cancer, will be presented today as a poster at the 112th AUA meeting. Abstract Title: "Intra-Prostatic Injection of PRX302 Focal Therapy in Treating Clinically Significant Low-Intermediate Risk Prostate Cancer: An Open Label, Proof-of-Concept Study" Presenting Author: Edward J. Bass, University College London, London, UK Poster Session: MP70: Prostate Cancer: Localized: Ablative Therapy 1 Time: May 15, 2017 from 7:00 a.m. - 9:00 a.m. ET The poster will be available on the Company's website at www.sophirisbio.com. About Sophiris Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin (PRX302), a first-in-class treatment for patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Topsalysin is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells. More than 400 patients have received treatment with topsalysin, which continues to appear to be safe and well tolerated. For more information, please visit www.sophirisbio.com. Company Contact: Peter Slover Chief Financial Officer (858) 777-1760 Corporate Communications Contact: Jason Spark Canale Communications (619) 849-6005 [email protected] To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sophiris-bio-presentstopsalysin-data-from-phase-2a-proof-of-concept-study-in-localized-prostate-cancer-at-112th-american-urologicalassociation-aua-meeting-300457015.html SOURCE Sophiris Bio Inc. News Provided by Acquire Media
